Wei Chi1, Lianyong Zhang1, Xue Wang1, Jingjing Li1, Fei Li1, Yuxia Ma2, Qianyun Zhang3. 1. Department of pulmonary and Critical Care Medicine ward II, Cangzhou Central Hospital, Xinhua West Road, 061000, Cangzhou, Hebei, China. 2. Department of Geriatrics, Cangzhou Central Hospital, 061000, Cangzhou, Hebei, China. 3. Department of pulmonary and Critical Care Medicine ward II, Cangzhou Central Hospital, Xinhua West Road, 061000, Cangzhou, Hebei, China. zhangqianyun001@163.com.
Abstract
BACKGROUND: Small cell lung cancer (SCLC) accounts for nearly 10-15% of all lung cancer cases. Although many chemotherapy drugs, such as cisplatin and etoposide, were approved as primary therapy for SCLC patients, the prognosis is poor. In this study, we aimed to explore novel therapeutic strategy against SCLC. METHODS: Two SCLC cell lines, LTEP-P and LTEP-P/DDP1.0, were treated with cisplatin, in the absence or presence of Nivolumab + Ipilimumab combination, and the cell viability was measured. Tumor size and mouse survival rate were examined upon different drug treatments. Protein levels of PD-1 and CTLA4 were detected in normal and SCLC cells by Western blot. Cellular cytotoxicity induced by T lymphocytes was measured by thymidine incorporation assay. Tumor infiltrated T cell populations from LTEP-P and LTEP/DDP1.0 tumor-bearing mice were analyzed by flow cytometry. RESULTS: LTEP-P cells, but not LTEP/DDP1.0 cells, exhibited decreased cell viability upon cisplatin, Nivolumab and Ipilimumab combinational treatment. T lymphocytes significantly inhibited the growth of LTEP-P cells in the presence of nivolumab and ipilimumab. The combinational therapy improved survival rate and inhibited tumor growth in LTEP-P tumor-bearing mice, but showed no effect on LTEP/DDP1.0 tumor-bearing mice. Nivolumab and Ipilimumab synergized with cisplatin in increasing CD8 + and CD4 + T cell population, while decreasing Treg population in LTEP-P tumor-bearing mice. CONCLUSIONS: The combinational therapy by cisplatin, Nivolumab and Ipilimumab could be an effective strategy against LTEP-P cells, accompanied with increased cytotoxic T cell populations, but has no significant effect against DDP-resistant lung adenocarcinoma cells.
BACKGROUND: Small cell lung cancer (SCLC) accounts for nearly 10-15% of all lung cancer cases. Although many chemotherapy drugs, such as cisplatin and etoposide, were approved as primary therapy for SCLC patients, the prognosis is poor. In this study, we aimed to explore novel therapeutic strategy against SCLC. METHODS: Two SCLC cell lines, LTEP-P and LTEP-P/DDP1.0, were treated with cisplatin, in the absence or presence of Nivolumab + Ipilimumab combination, and the cell viability was measured. Tumor size and mouse survival rate were examined upon different drug treatments. Protein levels of PD-1 and CTLA4 were detected in normal and SCLC cells by Western blot. Cellular cytotoxicity induced by T lymphocytes was measured by thymidine incorporation assay. Tumor infiltrated T cell populations from LTEP-P and LTEP/DDP1.0 tumor-bearing mice were analyzed by flow cytometry. RESULTS: LTEP-P cells, but not LTEP/DDP1.0 cells, exhibited decreased cell viability upon cisplatin, Nivolumab and Ipilimumab combinational treatment. T lymphocytes significantly inhibited the growth of LTEP-P cells in the presence of nivolumab and ipilimumab. The combinational therapy improved survival rate and inhibited tumor growth in LTEP-P tumor-bearing mice, but showed no effect on LTEP/DDP1.0 tumor-bearing mice. Nivolumab and Ipilimumab synergized with cisplatin in increasing CD8 + and CD4 + T cell population, while decreasing Treg population in LTEP-P tumor-bearing mice. CONCLUSIONS: The combinational therapy by cisplatin, Nivolumab and Ipilimumab could be an effective strategy against LTEP-P cells, accompanied with increased cytotoxic T cell populations, but has no significant effect against DDP-resistant lung adenocarcinoma cells.
Authors: Laurie E Gaspar; Erica J McNamara; E Greer Gay; Joe B Putnam; Jeffrey Crawford; Roy S Herbst; James A Bonner Journal: Clin Lung Cancer Date: 2011-10-14 Impact factor: 4.785
Authors: Antonio Rossi; Massimo Di Maio; Paolo Chiodini; Robin Michael Rudd; Hiroaki Okamoto; Dimosthenis Vasilios Skarlos; Martin Früh; Wendi Qian; Tomohide Tamura; Epaminondas Samantas; Taro Shibata; Francesco Perrone; Ciro Gallo; Cesare Gridelli; Olga Martelli; Siow-Ming Lee Journal: J Clin Oncol Date: 2012-04-02 Impact factor: 44.544
Authors: Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo Journal: Lancet Oncol Date: 2016-06-04 Impact factor: 41.316
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Wei Zhang; Luc Girard; Yu-An Zhang; Tomohiro Haruki; Mahboubeh Papari-Zareei; Victor Stastny; Hans K Ghayee; Karel Pacak; Trudy G Oliver; John D Minna; Adi F Gazdar Journal: Transl Lung Cancer Res Date: 2018-02